Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting

Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting

Science 37® and 3H Medi Solution Collaborate to Enable Decentralized Clinical Trials in Japan and Accelerate Patient Enrollment
Science 37® and CMIC Announce Partnership to Advance Decentralized Clinical Trials in Japan/APAC and Speed Drug Development
Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021
Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States
Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021
Solaris Pharma Receives FDA Approval for Generic Metrogel-Vaginal®
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites